These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36451848)

  • 21. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
    Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
    Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps].
    Klimek L; Chaker A; Deitmer T; Plontke SK; Wollenberg B; Bousquet J; Bachert C
    HNO; 2021 Nov; 69(11):868-877. PubMed ID: 33738558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
    Mullol J; Bachert C; Amin N; Desrosiers M; Hellings PW; Han JK; Jankowski R; Vodicka J; Gevaert P; Daizadeh N; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
    J Allergy Clin Immunol Pract; 2022 Apr; 10(4):1086-1095.e5. PubMed ID: 34628065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proposal for a Structured Outpatient Clinic for Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps in the First Year of Treatment.
    Torretta S; De Corso E; Nava N; Fraccaroli F; Ferrucci SM; Settimi S; Montuori C; Porru DP; Spanu C; D'Agostino G; Marzano AV; Pignataro L
    J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months.
    van der Lans RJL; Otten JJ; Adriaensen GFJPM; Hoven DR; Benoist LB; Fokkens WJ; Reitsma S
    Allergy; 2023 Oct; 78(10):2684-2697. PubMed ID: 37394895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
    Fujieda S; Matsune S; Takeno S; Asako M; Takeuchi M; Fujita H; Takahashi Y; Amin N; Deniz Y; Rowe P; Mannent L
    Laryngoscope; 2021 Jun; 131(6):E1770-E1777. PubMed ID: 33226139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up.
    Kiricsi A; Bella Z; Kraxner H; Szaloki T; Fent Z; Liktor B; Huszka J; Laszlo P; Gobol D; Helfferich F; Vaska Z; Piski Z; Juhasz-Loisch L; Horvath B; Galantai G; Krisztin N; Toth L; Bodi A; Matuz M; Lujber L; Hirschberg A
    Rhinology; 2024 Jun; ():. PubMed ID: 38848046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma.
    Gurnell M; Radwan A; Bachert C; Lugogo N; Cho SH; Nash S; Zhang H; Khan AH; Jacob-Nara JA; Rowe PJ; Deniz Y
    J Asthma Allergy; 2024; 17():1-8. PubMed ID: 38250137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.
    Scangas GA; Wu AW; Ting JY; Metson R; Walgama E; Shrime MG; Higgins TS
    Laryngoscope; 2021 Jan; 131(1):E26-E33. PubMed ID: 32243622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
    Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
    Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care.
    Galletti C; Barbieri MA; Ciodaro F; Freni F; Galletti F; Spina E; Galletti B
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.
    Chuang CC; Guillemin I; Bachert C; Lee SE; Hellings PW; Fokkens WJ; Duverger N; Fan C; Daizadeh N; Amin N; Mannent LP; Khan AH; Kamat S
    Laryngoscope; 2022 Feb; 132(2):259-264. PubMed ID: 34817082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.
    Kariyawasam HH
    Expert Rev Clin Immunol; 2020 Dec; 16(12):1115-1125. PubMed ID: 33148074
    [No Abstract]   [Full Text] [Related]  

  • 34. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis.
    Napolitano M; Maffei M; Patruno C; Leone CA; Di Guida A; Potestio L; Scalvenzi M; Fabbrocini G
    Dermatol Ther; 2021 Nov; 34(6):e15120. PubMed ID: 34472171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
    Dharmarajan H; Falade O; Lee SE; Wang EW
    Int Forum Allergy Rhinol; 2022 Aug; 12(8):986-995. PubMed ID: 34919344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective.
    Caminati M; Maule M; Benoni R; Bagnasco D; Beghè B; Braido F; Brussino L; Cameli P; Candeliere MG; Carpagnano GE; Costanzo G; Crimi C; D'Amato M; Del Giacco S; Guarnieri G; Yacoub MR; Micheletto C; Nicola S; Olivieri B; Pini L; Schiappoli M; Vaia R; Vianello A; Visca D; Spanevello A; Senna G
    Biomedicines; 2024 Feb; 12(2):. PubMed ID: 38397992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies.
    Geng B; Bachert C; Busse WW; Gevaert P; Lee SE; Niederman MS; Chen Z; Lu X; Khokhar FA; Kapoor U; Pandit-Abid N; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
    J Allergy Clin Immunol Pract; 2022 Mar; 10(3):732-741. PubMed ID: 34954123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sleep quality burden in chronic rhinosinusitis with nasal polyps and its modulation by dupilumab.
    Ferri S; Montagna C; Casini M; Malvezzi L; Pirola F; Russo E; Racca F; Messina MR; Puggioni F; Nappi E; Costanzo G; Del Moro L; Mercante G; Spriano G; Canonica GW; Paoletti G; Heffler E
    Ann Allergy Asthma Immunol; 2024 Jan; 132(1):69-75. PubMed ID: 37652235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-Life Study of Patient Preference for Dupilumab or Revision Surgery for Recurrent Chronic Rhinosinusitis with Nasal Polyps.
    Gangl K; Liu DT; Bartosik T; Campion NJ; Vyskocil E; Mueller CA; Knerer B; Eckl-Dorna J; Schneider S
    J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
    Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
    Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.